UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Genetic Basis for Cancer Treatment Decisions

Cell, 2012-02, Vol.148 (3), p.409-420

2012

Volltextzugriff (PDF)

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

Cancer treatment reviews, 2013-12, Vol.39 (8), p.935-946

2013

Volltextzugriff (PDF)

Strategies for optimizing combinations of molecularly targeted anticancer agents

Nature reviews. Drug discovery, 2006-08, Vol.5 (8), p.649-659

2006

Volltextzugriff (PDF)

Therapeutic targets: MTOR and related pathways

Cancer biology & therapy, 2006-09, Vol.5 (9), p.1065-1073

Dancey, Janet E.

2006

Volltextzugriff (PDF)

Rare cancers: a sea of opportunity

The lancet oncology, 2016-02, Vol.17 (2), p.e52-e61

2016

Volltextzugriff (PDF)

Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway

Journal of clinical oncology, 2012-08, Vol.30 (23), p.2919-2928

2012

Volltextzugriff (PDF)

Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

Journal of clinical oncology, 2011-08, Vol.29 (24), p.3278-3285

2011

Volltextzugriff (PDF)

Cancer Genomics: Technology, Discovery, and Translation

Journal of clinical oncology, 2012-02, Vol.30 (6), p.647-660

2012

Volltextzugriff (PDF)

Minding the gaps: assessing and addressing clinical research core competencies across a network of Canadian cancer centres

Frontiers in pharmacology, 2023, Vol.14, p.1294335-1294335

2023

Volltextzugriff (PDF)

Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents

Clinical cancer research, 2010-03, Vol.16 (6), p.1745-1755

2010

Volltextzugriff (PDF)

Targeting epidermal growth factor receptor—are we missing the mark?

The Lancet (British edition), 2003-07, Vol.362 (9377), p.62-64

2003

Volltextzugriff (PDF)

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

The lancet oncology, 2009-03, Vol.10 (3), p.247-257

2009

Volltextzugriff (PDF)

The Impact of COVID-19 on Academic Cancer Clinical Trials in Canada and the Initial Response from Cancer Centers

Current oncology (Toronto), 2022-03, Vol.29 (4), p.2435-2441

2022

Volltextzugriff (PDF)

CRAFT-A Proposed Framework for Decentralized Clinical Trials Participation in Canada

Current oncology (Toronto), 2021-09, Vol.28 (5), p.3857-3865

2021

Volltextzugriff (PDF)

A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Clinical cancer research, 2012-04, Vol.18 (8), p.2336-2343

2012

Volltextzugriff (PDF)

Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands

Journal of clinical oncology, 2007-09, Vol.25 (25), p.3978-3984

2007

Volltextzugriff (PDF)

Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study

Journal of clinical oncology, 2008-10, Vol.26 (30), p.4921-4927

2008

Volltextzugriff (PDF)

Advancing Academic Cancer Clinical Trials Recruitment in Canada

Current oncology (Toronto), 2021-07, Vol.28 (4), p.2830-2839

2021

Volltextzugriff (PDF)

A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group

Supportive care in cancer, 2010-04, Vol.18 (4), p.509-522

2010

Volltextzugriff (PDF)

Predictive factors for epidermal growth factor receptor inhibitors—The bull's-eye hits the arrow

Cancer Cell, 2004-05, Vol.5 (5), p.411-415

Dancey, Janet E.

2004

Volltextzugriff (PDF)

Inhibitors of the mammalian target of rapamycin

Expert opinion on investigational drugs, 2005-03, Vol.14 (3), p.313-328

Dancey, Janet E

2005

Volltextzugriff (PDF)

A Phase 2 study of perifosine in advanced or metastatic breast cancer

Breast cancer research and treatment, 2008-03, Vol.108 (1), p.87-92

2008

Volltextzugriff (PDF)

Assessing benefit in trials: Are we making progress in assessing progression in cancer clinical trials?

Cancer, 2015-06, Vol.121 (11), p.1728-1730

Dancey, Janet E.

2015

Volltextzugriff (PDF)

A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer

American journal of clinical oncology, 2010-12, Vol.33 (6), p.609-613

2010

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Gefitinib in Children With Refractory Solid Tumors: A Children’s Oncology Group Study

Journal of clinical oncology, 2005-09, Vol.23 (25), p.6172-6180

2005

Volltextzugriff (PDF)

1 – 25 von 131

Suche als RSS-Feed

Aktive Filter

KollektionEbook Central Perpetual and DDA

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(129)
Mit Volltextzugriff
(122)

Publikationsform

Artikel
(130)
Texte
(1)

Sprache

Englisch
(131)

Erscheinungsjahr

n.n

Thema

Humans
(93)
Science & Technology
(89)
Life Sciences & Biomedicine
(88)
Oncology
(62)
Female
(44)
Male
(39)
Biological And Medical Sciences
(35)
Medical Sciences
(35)
Tumors
(30)
Adult
(28)
Aged
(28)
Middle Aged
(28)
Antineoplastic Agents - Therapeutic Use
(25)
Neoplasms - Drug Therapy
(25)
Treatment Outcome
(23)
Clinical Trials As Topic
(18)
Clinical Trials
(17)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(16)
Antineoplastic Agents
(14)
Child
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Genetic Basis for Cancer Treatment Decisions

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

Strategies for optimizing combinations of molecularly targeted anticancer agents

Therapeutic targets: MTOR and related pathways

Rare cancers: a sea of opportunity

Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway

Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group

Cancer Genomics: Technology, Discovery, and Translation

Minding the gaps: assessing and addressing clinical research core competencies across a network of Canadian cancer centres

Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents

Targeting epidermal growth factor receptor—are we missing the mark?

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

The Impact of COVID-19 on Academic Cancer Clinical Trials in Canada and the Initial Response from Cancer Centers

CRAFT-A Proposed Framework for Decentralized Clinical Trials Participation in Canada

A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands

Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study

Advancing Academic Cancer Clinical Trials Recruitment in Canada

A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group

Predictive factors for epidermal growth factor receptor inhibitors—The bull's-eye hits the arrow

Inhibitors of the mammalian target of rapamycin

A Phase 2 study of perifosine in advanced or metastatic breast cancer

Assessing benefit in trials: Are we making progress in assessing progression in cancer clinical trials?

A multicenter phase II clinical trial of lapatinib (GW572016) in hormonally untreated advanced prostate cancer

Phase I and Pharmacokinetic Study of Gefitinib in Children With Refractory Solid Tumors: A Children’s Oncology Group Study

Aktive Filter

Suchergebnisse filtern